BCR-Abl inhibitor (Nanjing Sanhome Pharmaceutical)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug NameBCR-Abl inhibitor (Nanjing Sanhome Pharmaceutical)
Drug Alias Nameponatinib analog (Nanjing Sanhome Pharmaceutical)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesNanjing Sanhome Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNanjing Sanhome Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A